|Bid||185.25 x 900|
|Ask||186.45 x 800|
|Day's Range||175.44 - 185.83|
|52 Week Range||45.08 - 213.15|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.79|
• As of Sunday, the U.S. has reported 581,572 deaths from Covid-19, but that number is likely an undercount, Dr. Anthony Fauci told NBC’s “Meet the Press” on Sunday, referring to the tally from Johns Hopkins University. “I think there’s no doubt that we are and have been undercounting,” said Fauci, who is the director of the National Institute of Allergy and Infectious Diseases. When asked if the actual number could be more than 900,000, as estimated last week by the University of Washington, Fauci said that bigger number is “a bit more than I would have thought the undercounting was.”
BioNTech (NASDAQ: BNTX) recently raised guidance for the number of doses of its coronavirus vaccine that the biotech thinks it'll be able to produce this year. In this video from Motley Fool Live, recorded on April 5, Fool.com contributors Brian Orelli and Keith Speights discuss whether the increase will actually help the German drugmaker. Unfortunately, between a supply glut and the inability for developing companies to pay full price, the added capacity may not help BioNTech's bottom line that much.
BioNTech (NASDAQ: BNTX) is famous for its coronavirus vaccine, but the biotech has additional drug candidates in the works. In this video from Motley Fool Live, recorded on April 5, Fool.com Contributors Brian Orelli and Keith Speights discuss BioNTech's pipeline and what's in store for the company's future.